HIV/AIDS Topics CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 06 April 2016 00:00
- Written by Michael Carter
Merck's MK-8591, an investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to 6 months after dosing could represent a "paradigm shift" in HIV therapy and prophylaxis, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.
CROI 2016: VRC01 Antibody Delays But Does Not Prevent HIV Rebound After ART Interruption
- Details
- Category: Search for a Cure
- Published on Thursday, 31 March 2016 00:00
- Written by Liz Highleyman
VRC01, a broadly neutralizing antibody targeting HIV's CD4 binding site, was able to modestly delay the return of viral replication following interruption of antiviral therapy (ART), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. VRC01 did not maintain viral suppression on its own, but it may play a role in combination therapy for HIV treatment or a functional cure.
CROI 2016: Personalized Counseling Improves Rate of Entry into HIV Care
- Details
- Category: Cascade of Care
- Published on Wednesday, 30 March 2016 00:00
- Written by Keith Alcorn
Entry into HIV care can be increased by around 40% if people receive a point-of-care CD4 test and counseling sessions to overcome personal barriers to seeking HIV care, according to a large randomized study in South Africa presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last month in Boston. However, the study also found that only half of the people who received the most effective linkage intervention and who were in need of immediate treatment made it onto antiretroviral therapy (ART) within 6 months of their HIV diagnosis, highlighting the need for further improvements in linkage to HIV care.
Johns Hopkins Team Performs Pioneering HIV+ to HIV+ Liver and Kidney Transplants
- Details
- Category: When to Start ART?
- Published on Wednesday, 30 March 2016 00:00
- Written by Liz Highleyman
Doctors at Johns Hopkins announced that they recently performed the first-ever liver transplant and the first kidney transplant in the U.S. from an HIV-positive donor to a recipient living with HIV, made possible by the 2013 HIV Organ Policy Equity (HOPE) Act. Both transplants were successful and the patients are doing "extremely well," infectious disease specialist Christine Durand said at a March 30 press conference.
CROI 2016: More People with HIV Are Achieving Viral Suppression in U.S.
- Details
- Category: Cascade of Care
- Published on Thursday, 24 March 2016 00:00
- Written by Liz Highleyman
A growing proportion of people with HIV are reaching an undetectable viral load on antiretroviral therapy (ART), according to a pair of studies from the U.S. Centers for Disease Control and Prevention (CDC) presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. Despite this improvement, however, a substantial number of people are still not achieving viral suppression, putting them at risk for disease progression and onward transmission.
CROI 2016: Dose-Finding Trials of Antibody-Based Drugs for HIV Prevention To Start Soon
- Details
- Category: Search for a Cure
- Published on Wednesday, 30 March 2016 00:00
- Written by Gus Cairns
The next generation of pre-exposure prophylaxis (PrEP), and even HIV treatment, may consist of antibodies that could be given as an intravenous infusion or an injection into muscle, according to 2 presenters at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.
CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 14 March 2016 00:00
- Written by Liz Highleyman
A long-acting bioengineered "combinectin" molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any of the 3 separate mechanisms in a laboratory study, and lowered viral load in humanized mice, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.
More Articles...
- CROI 2016: Removing Clinic Barriers to Rapid ART in Uganda Enables 70% to Start on Same Day
- Updated U.S. Guidelines for Antiretroviral Treatment of Children with HIV
- CROI 2016: START Study Shows People Starting HIV Treatment Earlier Have Better Quality of Life
- FDA Approves Second TAF-Containing Single-Tablet HIV Regimen
- CROI 2016: Expanding Treatment and PrEP Could Prevent 185,000 New HIV Infections, CDC Says
Web Design and Development by